mechan
acquir
immun
system
stimul
effect
vaccin
take
week
vaccin
exposur
virul
organ
acquir
immun
system
fulli
function
maintain
optim
immun
function
prevent
infecti
diseas
requir
good
manag
practic
prevent
suppress
immun
system
sound
vaccin
practic
induc
optim
acquir
immun
articl
briefli
review
basic
type
immun
factor
relev
feedlot
cattl
shown
suppress
immun
function
known
basi
protect
acquir
immun
common
bovin
respiratori
pathogen
caus
signific
loss
feedlot
anim
nativ
defens
mechan
includ
enzym
saliva
tear
acid
stomach
fatti
acid
skin
normal
flora
mucos
surfac
nativ
defens
mechan
also
includ
complement
system
phagocyt
white
blood
cell
capabl
kill
bacteria
virus
nativ
defens
mechan
function
immedi
infecti
agent
enter
bodi
even
anim
vaccin
complement
system
phagocyt
cell
work
effici
vaccin
anim
howev
bacteria
virus
capabl
produc
diseas
evolv
way
avoid
easili
kill
nativ
defens
mechan
order
anim
adequ
protect
econom
import
infecti
diseas
must
either
previous
expos
diseas
vaccin
diseas
develop
humor
immun
cellmedi
immun
mucos
immun
humor
immun
due
presenc
either
immunoglobulin
g
igg
igm
bloodstream
anim
vaccin
b
lymphocyt
respond
vaccin
produc
igmand
iggclass
antibodi
antibodi
protein
circul
bloodstream
attach
infecti
agent
encount
blood
tissu
antibodi
alon
capabl
kill
infecti
agent
presenc
circul
igg
igm
may
help
control
diseas
agglutin
infecti
agent
therebi
reduc
number
infecti
particl
virus
facilit
remov
phagocytosi
bind
neutral
toxin
bind
infecti
agent
block
attach
cell
surfac
bind
infecti
agent
initi
classic
pathway
complement
activ
opson
infecti
agent
facilit
phagocytosi
mediat
attach
cytotox
cell
surfac
infect
cell
infect
cell
may
destroy
antibodydepend
cellmedi
cytotox
diseasecaus
organ
howev
resist
control
activ
circul
antibodi
organ
must
attack
destroy
cellmedi
immun
system
control
secretori
iga
system
term
cellmedi
immun
refer
immun
mediat
primarili
lymphocyt
lymphocyt
two
basic
method
protect
anim
diseas
lymphocyt
call
cytotox
cell
make
contact
cell
present
foreign
antigen
surfac
viral
antigen
antigen
intracellular
bacteria
cell
specif
recogn
foreign
antigen
kill
cell
surfac
effect
prevent
viru
replic
cell
second
method
cell
use
fight
infect
secret
cytokin
cytokin
glycoprotein
molecul
activ
cell
immun
system
aggress
includ
macrophag
neutrophil
natur
killer
lymphocyt
activ
macrophag
neutrophil
effici
kill
bacteria
especi
facult
intracellular
bacteri
pathogen
like
brucella
mycobacteria
salmonella
listeria
activ
natur
killer
cell
effici
kill
virusinfect
cell
cell
secret
cytokin
enhanc
kill
macrophag
neutrophil
natur
killer
cell
call
thelper
cell
lymphocyt
also
essenti
secret
cytokin
control
type
amount
antibodi
produc
b
lymphocyt
cell
call
lithelp
cell
therefor
product
normal
antibodi
respons
requir
tiymphocyt
help
activ
thelper
cell
usual
consid
part
cellmedi
immun
protect
anim
infect
mucos
surfac
intestin
tract
respiratori
tract
mammari
gland
reproduct
tract
especi
difficult
immun
system
antibodi
respons
humor
immun
white
blood
cell
respons
cellmedi
immun
found
bloodstream
tissu
extent
includ
submucos
surfac
howev
found
mucos
surfac
therefor
help
prevent
invas
mucos
surfac
effect
control
infect
mucos
surfac
mucos
surfac
lower
respiratori
tract
reproduct
tract
mammari
gland
igg
white
blood
cell
found
rel
abund
abl
provid
signific
amount
protect
abl
function
effect
bloodstream
tissu
protect
mucos
surfac
due
larg
part
special
class
antibodi
call
secretori
iga
secretori
iga
tend
produc
respons
pathogen
enter
mucos
surfac
secretori
iga
secret
onto
mucos
surfac
may
bind
mucu
present
fairli
high
concentr
secretori
iga
resist
destruct
proteolyt
enzym
mucos
surfac
capabl
break
iga
igm
iga
predomin
immunoglobulin
found
milk
monogastr
import
protect
gastrointestin
tract
neonat
pathogen
rumin
iggl
predomin
class
antibodi
milk
protect
gastrointestin
tract
newborn
mucos
surfac
rumin
tend
high
concentr
iggl
well
iga
bovin
respiratori
diseas
brd
complex
extens
investig
recent
year
numer
vaccin
antibiot
develop
prescrib
control
despit
effort
brd
still
major
problem
pathogenesi
etiolog
incomplet
understood
respiratori
diseas
particularli
preval
first
day
calv
wean
transport
place
feedlot
ie
ship
fever
econom
import
clinic
sign
lesion
death
loss
ship
fever
usual
attribut
bacteri
pneumonia
due
pasteurella
haemolytica
pasteurella
multocida
haemophilu
somnu
bacteria
commonli
found
nasopharyng
area
healthi
anim
normal
condit
bacteria
unabl
move
lower
respiratori
tract
caus
pneumonia
fact
lung
normal
healthi
cattl
withstand
challeng
surprisingli
larg
number
bacteria
without
seriou
consequ
anim
stress
howev
respiratori
viral
infect
otherwis
immunosuppress
sever
pneumonia
establish
rel
small
number
bacteria
observ
led
concept
brd
multifactori
etiolog
involv
complex
interact
stressor
virus
perhap
immunosuppress
factor
act
separ
togeth
suppress
defens
mechan
lung
predispos
anim
bacteri
pneumonia
ampl
evid
environment
physic
psycholog
stress
distress
lead
increas
suscept
diseas
increas
suscept
least
partial
due
alter
immun
function
gener
bodili
respons
distress
releas
adrenocorticotropin
anterior
pituitari
gland
stimul
adren
cortex
increas
synthesi
secret
cortisol
hydrocortison
cortisol
respons
mani
effect
distress
immun
system
sever
stressor
sometim
associ
introduct
cattl
feedlot
proven
result
increas
plasma
cortisol
level
condit
includ
castrat
dehorn
wean
handl
forc
exercis
acut
pain
transport
evid
high
plasma
cortisol
concentr
affect
sever
aspect
host
includ
decreas
antibodi
respons
primari
immun
decreas
lymphocyt
function
lead
impair
cellmedi
immun
inhibit
phagocyt
cell
abil
enter
tissu
destroy
bacteria
level
endorphin
catecholamin
insulin
glucagon
growth
hormon
prolactin
thyroid
hormon
melatonin
also
alter
stress
hormon
may
alter
immun
function
well
effect
immun
system
understood
well
cortisol
import
effect
elev
cortisol
concentr
administr
pharmacolog
dose
glucocorticoid
eg
dexamethason
recrudesc
herpesvirus
bovin
herpesviru
bhvl
bhvi
recrudesc
otherwis
healthi
cattl
stress
dexamethason
treatment
done
even
anim
antibodi
titer
recrudesc
latent
bhvi
infect
anim
stress
lead
spread
bhvi
throughout
herd
like
herpesvirus
bhvi
harbor
latent
state
anim
recov
initi
infect
even
modifi
live
viru
mlv
vaccin
strain
recrudesc
shed
influenc
glucocorticoid
one
clinic
applic
dexamethason
treatment
cattl
suffer
bronchial
pneumonia
reduc
inflammatori
respons
lung
shortterm
improv
clinic
sign
often
occur
howev
experiment
shown
dexamethason
administr
combin
antibacteri
antihistamin
therapi
treatment
bronchial
pneumonia
cattl
outcom
poorer
respons
treatment
relaps
greater
death
occur
decreas
inflammatori
respons
lung
dexamethason
also
impair
activ
host
defens
mechan
thu
allow
increas
bacteri
replic
gener
glucocorticoid
use
part
treatment
regimen
brd
unless
inflammatori
respons
lung
life
threaten
clinician
confid
antimicrobi
agent
use
control
bacteri
infect
best
evid
virus
play
import
role
predispos
bacteri
pneumonia
come
epidemiolog
data
indic
recent
serolog
convers
respiratori
viru
associ
bacteri
pneumonia
challeng
experi
cattl
infect
viru
infect
day
later
aerosol
p
haemolytica
p
multocida
cattl
preinfect
either
bhvl
parainfluenza
viru
bovin
viral
diarrhea
bvd
viru
develop
sever
bacteri
pneumonia
although
nonvirusinfect
control
cattl
abl
clear
bacteria
lung
virus
may
number
effect
antibacteri
defens
mechan
lung
includ
impair
mucociliari
clearanc
suppress
phagocyt
cell
function
interfer
lymphocyt
function
rel
import
effect
known
probabl
combin
activ
respons
predisposit
bacteri
pneumonia
studi
shown
simultan
infect
bvd
viru
bovin
respiratori
syncyti
viru
brsv
synergist
increas
patholog
effect
individu
viru
number
respiratori
virus
cattl
inhibit
mucociliari
clearanc
ciliat
respiratori
epithelium
eg
bhvl
viru
bvd
viru
brsv
decreas
mucociliari
clearanc
often
cite
primari
reason
greater
suscept
bacteri
pneumonia
evid
suggest
howev
import
impair
bactericid
mechan
within
lung
conclus
base
observ
rate
bacteri
kill
within
healthi
lung
greatli
exce
rate
mucociliari
transport
lung
period
increas
suscept
bacteri
pneumonia
coincid
time
inhibit
mucociliari
clearanc
viral
infect
current
consensu
seem
suppress
function
phagocyt
cell
lung
alveolar
macrophag
neutrophil
primari
factor
predispos
bacteri
infect
phagocyt
cell
essenti
kill
bacteria
find
way
lower
respiratori
tract
remov
lung
alveolar
macrophag
predomin
phagocyt
healthi
lung
import
surveil
remov
foreign
materi
includ
bacteria
alveoli
alveolar
macrophag
unabl
control
infect
lung
expos
larg
challeng
dose
bacteria
neutrophil
migrat
alveoli
bronchiol
rapidli
soon
within
hour
becom
predomin
cell
type
neutrophil
quit
activ
phagocyt
alli
potent
bactericid
mechan
includ
gener
toxic
oxygen
product
eg
hydrogen
peroxid
superoxid
anion
hydroxyl
radic
releas
cation
antibacteri
peptid
hydrolyt
enzym
addit
bactericid
product
also
damag
pulmonari
tissu
infect
brought
control
rel
rapidli
neutrophil
induc
consider
damag
lung
evid
bhvl
viru
bvd
viru
brsv
impair
alveolar
macrophag
function
bhvl
bvd
viru
also
inhibit
neutrophil
function
effect
viru
brsv
neutrophil
function
appar
determin
import
aspect
alveolar
macrophag
neutrophil
function
activ
cytokin
secret
lymphocyt
phagocyt
activ
becom
aggress
effect
control
bacteri
infect
interf
lymphocyt
function
brd
virus
may
inhibit
alveolar
macrophag
neutrophil
activ
leav
anim
suscept
bacteri
pneumonia
bvd
viru
shown
inhibit
aspect
neutrophil
function
impair
bacteri
clearanc
blood
lessen
abil
calv
clear
bhvi
lung
facilit
pulmonari
infect
p
haemolytica
least
one
mlv
vaccin
strain
bvd
viru
also
shown
capabl
suppress
lymphocyt
neutrophil
function
suppress
neutrophil
function
last
week
infect
either
virul
mlv
strain
cattl
given
adrenocorticotrophin
increas
serum
cortisol
level
time
receiv
mlv
bvd
vaccin
mark
suppress
neutrophil
function
cattl
receiv
either
modifi
live
bvd
viru
adrenocorticotrophin
impli
stress
bvd
viru
act
synergist
caus
immunosuppress
wors
either
would
caus
alon
clinic
import
immunosuppress
current
use
mlv
bvd
vaccin
unknown
probabl
problem
use
healthi
anim
good
manag
condit
bovin
immunodefici
viru
biv
lentiviru
antigen
genet
homolog
human
immunodefici
viru
true
preval
biv
infect
cattl
unit
state
unknown
variou
serolog
survey
detect
infect
rate
experiment
infect
biv
associ
chang
circul
lymphocyt
number
alter
monocyt
decreas
neutrophil
function
chang
rel
minor
howev
experiment
biv
infect
shown
lead
clinic
appar
immunodefici
syndrom
potenti
impact
natur
occur
infect
biv
suscept
diseas
feedlot
cattl
still
unknown
sever
virus
associ
brd
complex
includ
bovin
adenoviru
coronaviru
herpesviru
movar
rhinovirus
reovirus
bovin
parvoviru
littl
known
immunosuppress
effect
virus
cattl
howev
logic
assum
infect
may
render
cattl
suscept
bacteri
pneumonia
mycoplasma
speci
mycoplasma
hovi
mycoplasma
dispar
ureaplasma
also
may
import
factor
etiolog
brd
infect
agent
uncompl
factor
usual
result
subclin
pneumonia
mycoplasma
probabl
playa
larger
role
brd
predispos
factor
secondari
bacteri
infect
primari
pathogen
infect
bovi
report
enhanc
sever
pneumonia
caus
p
haemolytica
mechan
mycoplasma
predispos
secondari
infect
clear
induct
inflamm
impair
lymphocyt
function
inhibit
mucociliari
transport
inhibit
neutrophil
function
suggest
possibl
contribut
nutrit
play
import
role
maintain
optim
immun
function
resist
brd
topic
cover
anoth
articl
issu
immunosuppress
due
administr
glucocorticoid
cattl
shown
exacerb
clinic
sign
coccidiosi
addit
evid
coccidiosi
immunosuppress
predispos
secondari
infect
feed
coccidiostat
feedlot
cattl
associ
reduc
shed
coccidi
oocyst
reduc
respiratori
diseas
subclin
clinic
coccidiosi
also
shown
suppress
neutrophil
function
cattl
substanc
secret
nematod
progress
larval
stage
shown
suppress
prolifer
bovin
lymphocyt
therefor
control
coccidiosi
parasit
feedlot
cattl
import
maintain
optim
immun
function
resist
infecti
diseas
bhvl
also
refer
infecti
bovin
rhinotrach
ibr
alpha
herpesviru
characterist
protect
immun
bhvi
similar
alpha
herpesvirus
antibodi
titer
measur
serum
neutral
sn
test
protect
anim
infect
evid
passiv
antibodi
calf
receiv
colostrum
provid
solid
protect
infecti
challeng
passiv
acquir
antibodi
also
prevent
mlv
vaccin
induc
antibodi
respons
calf
matern
antibodi
blockag
mlv
vaccin
even
occur
serum
neutral
titer
low
calf
receiv
lot
colostrum
high
titer
may
month
old
capabl
respond
mlv
vaccin
product
antibodi
even
though
mlv
vaccin
may
induc
antibodi
respons
possibl
may
induc
memori
respons
face
matern
antibodi
calf
subsequ
expos
virul
viru
may
capabl
respond
rapidli
viral
challeng
degre
protect
evid
indic
vaccin
presenc
matern
antibodi
pseudorabi
viru
pig
anoth
alpha
herpesviru
stimul
immunolog
memori
even
though
antibodi
respons
occur
immunolog
memori
shown
provid
partial
protect
diseas
challeng
pseudorabi
viru
pig
also
evid
like
true
mlv
bhvl
vaccin
use
presenc
matern
antibodi
calv
import
characterist
herpesvirus
anim
recov
diseas
latent
infect
viru
rest
life
viru
resid
ganglia
nerv
quiescent
state
even
mlv
bhvl
vaccin
shown
latent
infect
cattl
immun
system
capabl
clear
latent
infect
anim
stress
treat
glucocorticoid
later
life
viru
like
recrudesc
shed
even
anim
high
serum
neutral
antibodi
titer
therefor
serum
neutral
antibodi
prevent
infect
prevent
recrudesc
shed
latent
bhvl
latent
infect
anim
shed
bhvl
may
show
clinic
sign
sourc
infect
anim
herd
infect
bhvl
establish
cellmedi
immun
respons
probabl
need
order
bring
infect
control
cytotox
lymphocyt
thought
import
control
infect
seem
import
antigen
differ
bhvl
isol
immun
one
isol
bhvl
one
vaccin
strain
viru
appear
provid
good
cross
protect
field
isol
therefor
sn
titer
measur
bhvl
viru
laboratori
less
equal
neutral
bhvl
viru
antibodi
titer
determin
enzymelink
immunosorb
assay
may
may
measur
protect
serum
neutral
antibodi
depend
natur
antigen
use
enzymelink
immunosorb
assay
sn
antibodi
titer
approxim
greater
shown
protect
diseas
induc
bvd
viru
major
problem
howev
immun
bvd
viru
great
deal
antigen
divers
among
bvd
viru
isol
bvd
viru
like
rna
virus
high
mutat
rate
result
almost
unlimit
antigen
divers
among
isol
gene
bvd
code
protein
major
surfac
glycoprotein
immunodomin
antibodi
product
major
epitop
viru
neutral
gene
repres
one
hypervari
region
bvd
viru
genom
hypervari
may
due
select
pressur
immun
system
heterogen
protein
less
import
viru
neutral
epitop
limit
abil
antibodi
respons
one
strain
bvd
viru
protect
wide
array
possibl
strain
anim
may
expos
sn
antibodi
titer
singl
serum
sampl
may
vari
depend
bvd
viru
isol
use
sn
assay
anim
probabl
protect
isol
serum
neutral
titer
approxim
greater
antibodi
serum
protect
isol
bvd
viru
field
outbreak
imposs
predict
antigen
type
bvd
viru
anim
go
expos
appar
singl
vaccin
strain
bvd
viru
even
combin
vaccin
strain
capabl
provid
crossprotect
sn
antibodi
titer
potenti
virul
bvd
viru
isol
may
encount
littl
known
role
cellmedi
immun
either
cytotox
cell
thelper
cell
protect
bvd
virusinduc
diseas
like
cellmedi
immun
import
recoveri
infect
quit
possibl
cellmedi
immun
especi
provid
cytotox
lymphocyt
provid
better
crossprotect
immun
differ
bvd
viru
isol
antibodi
true
anim
develop
cellmedi
immun
better
protect
bvd
viru
challeng
mlv
vaccin
like
induc
cytotox
lymphocyt
kill
vaccin
may
provid
better
crossprotect
immun
varieti
bvd
viru
isol
hypothesi
fit
commonli
held
percept
mlv
vaccin
provid
better
immun
bvd
viru
kill
vaccin
remain
proven
experiment
recent
two
separ
genotyp
bvd
viru
type
type
bvd
virus
potenti
produc
sever
acut
infect
even
adult
anim
homolog
genotyp
tend
induc
better
crossneutr
antibodi
titer
heterolog
genotyp
typel
mlv
bvd
vaccin
shown
provid
protect
virul
challeng
bvd
viru
probabl
due
crossprotect
cellmedi
immun
respons
critic
factor
control
bvd
viru
infect
herd
probabl
cattl
popul
whole
prevent
infect
fetu
develop
persist
infect
calv
scant
data
abil
vaccin
administ
cow
prevent
infect
fetu
cow
becom
expos
virul
bvd
viru
experi
conduct
use
kill
bvd
viru
vaccin
cow
subsequ
challeng
virul
bvd
viru
pregnanc
case
vaccin
provid
adequ
immun
prevent
fetal
infect
one
experi
use
three
dose
kill
vaccin
evid
fetal
protect
experiment
challeng
obtain
consid
evid
like
kill
vaccin
induc
titer
greater
cow
particular
isol
bvd
viru
protect
fetu
becom
infect
howev
like
strain
bvd
viru
antigen
alli
differ
vaccin
viru
cow
fetu
protect
possibl
mlv
vaccin
administ
cow
prior
pregnanc
may
provid
better
crossprotect
immun
varieti
isol
describ
nevertheless
author
unawar
experi
demonstr
mlv
vaccin
administ
cow
capabl
protect
fetu
infect
fetal
protect
experi
expens
perform
need
answer
import
question
regard
vaccin
efficaci
circul
antibodi
seem
provid
good
immun
brsvinduc
diseas
evid
observ
calv
passiv
antibodi
usual
protect
brsvinduc
infect
diseas
howev
calv
recov
diseas
protect
reinfect
least
natur
protect
immun
clearli
understood
evid
suggest
strong
iga
memori
respons
associ
protect
cytotox
tiymphocyt
respons
f
protein
brsv
may
protect
diseas
one
seri
experi
calv
without
matern
antibodi
prime
live
brsv
via
respiratori
tract
protect
associ
strong
rapid
mucos
antibodi
memori
respons
challeng
serum
mucos
antibodi
present
time
challeng
problem
brsv
vaccin
immun
matern
antibodi
provid
good
protect
interfer
activ
immun
calf
assay
antibodi
product
present
real
problem
brsv
tend
caus
diseas
calv
young
effect
vaccin
matern
antibodi
addit
research
need
character
natur
protect
immun
brsv
develop
vaccin
effect
immun
young
calf
presenc
matern
antibodi
recent
year
shown
antibodi
p
haemolytica
leukotoxin
surfac
capsular
antigen
import
help
protect
calv
p
haemolyticainduc
pneumonia
lb
measur
antibodi
titer
p
haemolytica
would
best
measur
antileukotoxin
antibodi
titer
anticapsular
antibodi
titer
titer
correl
best
immun
calf
directli
challeng
lung
p
haemolytica
lymphocyt
mediastin
lymph
node
calv
vaccin
mlv
p
haemolytica
vaccin
recov
p
haemolytica
challeng
secret
gamma
interferon
stimul
outer
membran
protein
p
haemolytica
indic
calv
develop
thelper
cellmedi
immun
respons
p
haemolytica
protect
pneumon
lesion
close
correl
antileukotoxin
antibodi
respons
lymphocyt
gamma
interferon
product
howev
import
compon
pathogenesi
natur
occur
p
haemolytica
pneumonia
colon
upper
respiratori
tract
p
haemolytica
isol
low
number
upper
respiratori
tract
normal
healthi
calv
viral
infect
stress
may
allow
p
haemolytica
nasal
pharyng
area
grow
larg
number
lead
inhal
microcoloni
deep
lung
microcoloni
may
success
avoid
immun
defens
alveolu
produc
sever
pneumonia
littl
known
abil
current
vaccin
inhibit
colon
upper
respiratori
tract
p
haemolytica
research
need
design
test
vaccin
capabl
prevent
reduc
upper
respiratori
colon
p
haemolytica
much
known
natur
protect
immun
h
somnusinduc
pneumonia
h
somnu
number
potenti
virul
factor
studi
includ
endotoxin
antibodi
bind
protein
surfac
nucleotid
hemolysin
like
antibodi
potenti
virul
factor
may
help
protect
calf
h
somnusinduc
pneumonia
howev
scant
data
support
hypothesi
addit
two
protein
isol
h
somnu
protein
protein
implic
import
antigen
induc
role
thelper
cell
secretori
iga
respons
protect
h
somnusinduc
pneumonia
thoroughli
investig
evid
gamma
interferon
produc
athelp
cell
immun
respons
help
protect
calf
h
somnusinduc
pneumonia
use
live
kill
vaccin
advantag
one
usual
disadvantag
mlv
vaccin
attribut
includ
strong
longlast
immun
respons
achiev
fewer
dose
less
relianc
adjuv
possibl
stimul
interferon
product
stimul
effector
compon
cellmedi
immun
cytotox
lymphocyt
fact
bacteria
viru
may
look
behav
like
pathogen
form
organ
advantag
kill
vaccin
stabl
storag
unlik
caus
diseas
result
residu
virul
revers
numer
brand
vaccin
provid
varieti
combin
live
kill
antigen
includ
ibr
viru
bvd
viru
viru
brsv
pasteurella
sp
h
somnu
antigen
ibr
viru
vaccin
avail
mlv
form
intramuscular
subcutan
intranas
use
well
kill
chemic
alter
viru
form
intramuscular
use
intramuscular
mlv
vaccin
thought
quickli
induc
immun
follow
proper
administr
singl
dose
intranas
mlv
vaccin
induc
immun
mucos
surfac
stimul
acquir
mucos
immun
product
interferon
may
use
safe
calv
suckl
pregnant
cow
induc
immun
face
residu
matern
antibodi
titer
howev
difficult
administ
kill
viru
vaccin
requir
two
dose
administ
interv
order
induc
immun
along
higher
cost
concern
shorter
durat
immun
make
less
practic
use
typic
feedlot
set
review
ibr
viru
vaccin
clinic
efficaci
studi
result
posit
neutral
howev
none
neg
studi
date
may
appli
current
cattl
feed
manag
practic
north
america
field
trial
use
ibr
mlv
vaccin
arriv
incid
upper
respiratori
diseas
reduc
unvaccin
calv
vaccin
rr
p
ooooo
us
welldesign
trial
use
ibr
mlv
vaccin
given
arriv
fail
show
benefit
health
perform
anoth
report
fail
show
ibr
viru
vaccin
efficaci
involv
addit
antigen
discuss
section
multipl
antigen
current
consensu
includ
ibr
viru
precondit
arriv
vaccin
regimen
bvd
viru
vaccin
avail
mlv
kill
viru
form
one
controversi
vaccin
use
cattl
unit
state
lack
largescal
efficaci
trial
widespread
infect
cattl
popul
unit
state
presenc
persist
infect
cattl
subsequ
develop
mucos
diseas
emerg
role
heterolog
novel
strain
viru
combin
creat
confus
controversi
clear
consensu
concern
use
measur
certain
immun
paramet
suggest
immunosuppress
follow
use
mlv
may
concern
howev
lack
complic
follow
use
larg
number
cattl
suggest
may
practic
concern
use
mlv
may
greater
concern
highli
stress
cattl
wellcontrol
studi
evalu
avail
case
dose
time
requir
kill
bvd
viru
vaccin
sever
limit
feedlot
set
reliabl
peerreview
report
field
trial
examin
clinic
effect
bvd
viru
vaccin
north
american
beef
cattl
base
research
use
scientif
valid
method
clinic
relev
outcom
use
base
extrapol
challeng
licens
data
person
prefer
main
concern
bvd
fetal
infect
result
abort
congenit
defect
develop
persist
infect
carrier
constant
sourc
infect
viru
viru
cross
placenta
suscept
pregnant
cattl
result
fetal
infect
either
exposur
field
viru
improp
use
intramuscular
bvd
mlv
vaccin
occur
first
month
pregnanc
fetal
loss
immun
toler
may
result
fetal
infect
last
trimest
gestat
usual
result
birth
immun
seroposit
healthi
calf
current
inform
conclus
document
durat
protect
follow
natur
infect
use
bvd
mlv
vaccin
although
avail
inform
indic
infect
confer
singl
year
protect
fetu
seroneg
cattl
vaccin
bvd
mlv
vaccin
last
trimest
pregnanc
calv
seroconvert
fetus
wherea
cattl
seroposit
calv
indic
transplacent
infect
previous
expos
dam
occur
critic
studi
compar
abil
bvd
mlv
kill
vaccin
protect
fetu
field
situat
avail
current
time
believ
optimum
protect
beef
breed
herd
depend
activ
immun
bvd
mlv
vaccin
prior
breed
lo
ensur
respons
vaccin
administ
replac
heifer
two
time
wean
month
age
breed
final
inject
least
month
breed
order
avoid
detriment
effect
concept
although
document
use
differ
strain
serotyp
mlv
vaccin
inject
propos
expand
rang
cross
protect
genet
antigen
instabl
bvd
viru
may
result
emerg
isol
reduc
antigen
cross
reactiv
import
specif
circul
antibodi
effect
cellular
immun
due
viral
mutat
larg
unansw
time
temperaturesensit
bvd
mlv
vaccin
shown
safe
induc
seroconvers
pregnant
cattl
kill
singerstrain
vaccin
prevent
clinic
sign
follow
intravn
challeng
pregnant
cow
vaccin
polyval
kill
bvd
viru
vaccin
challeng
day
gestat
show
resist
fetal
infect
compar
nonvaccin
control
long
durat
immun
cross
protect
serotyp
follow
use
mlv
vaccin
make
prefer
use
beef
breed
herd
opportun
plan
vaccin
noncrit
stage
product
time
minim
stress
avail
make
infect
field
strain
virus
critic
period
fetal
develop
less
like
immun
declin
enough
permit
natur
infect
may
stimul
immedi
immun
respons
without
sever
diseas
consequ
may
basi
maintain
longterm
immun
depend
circumst
herd
annual
biannual
less
frequent
mlv
vaccin
inject
cow
calv
breed
may
recommend
brsv
vaccin
avail
mlv
inactiv
viru
form
recoveri
natur
infect
respiratori
syncyti
viru
engend
protect
immun
speci
unlik
vaccin
prevent
subsequ
infect
nevertheless
may
still
possibl
vaccin
attenu
clinic
sign
subsequ
infect
reduc
time
recoveri
one
experiment
challeng
small
number
calv
show
passiv
antibodi
reduc
patholog
associ
moreov
report
improv
gain
feed
mix
result
report
studi
investig
clinic
efficaci
brsv
vaccin
calv
arriv
statist
signific
benefit
brsv
vaccin
shown
auctionor
marketpurchas
transport
calv
vaccin
calv
two
time
less
like
treat
brd
complex
p
oooool
freshli
wean
transport
calv
time
less
like
treat
brd
complex
p
oool
statist
signific
benefit
brsv
vaccin
shown
two
class
calv
low
morbid
includ
precondit
calv
p
freshli
wean
calv
transport
p
canadian
studi
result
five
separ
trial
design
assess
brsv
vaccin
efficaci
equivoc
calv
vaccin
wean
howev
reduct
treatment
rate
report
calv
vaccin
arriv
benefit
found
vaccin
arriv
yearl
two
addit
trial
involv
calv
one
trial
involv
stocker
cattl
fail
demonstr
benefit
brsv
vaccin
arriv
although
evid
support
brsv
vaccin
usag
naiv
mismanag
calv
inclus
vaccin
regimen
univers
studi
show
viru
compromis
innat
defens
respiratori
tract
mani
older
cattl
arriv
feedlot
like
immun
valu
viru
vaccin
yearl
cattl
question
vaccin
may
valuabl
prewean
arriv
program
less
immunolog
experienc
calv
reliabl
peerreview
report
field
trial
examin
clinic
effect
viru
vaccin
north
american
beef
cattl
base
research
use
scientif
valid
method
clinic
relev
outcom
practic
matter
difficult
select
multiviru
brd
vaccin
includ
viru
make
inclus
less
issu
find
report
literatur
equivoc
use
recent
avail
pasteurella
sp
vaccin
feedlot
arriv
largest
bodi
pasteurella
sp
vaccin
data
exist
p
haemolytica
toxoid
three
studi
shown
statist
signific
reduct
morbid
mortal
calv
administ
p
haemolytica
toxoid
arriv
nevertheless
two
clinic
trial
show
signific
effect
vaccin
given
arriv
week
shipment
arriv
health
perform
vaccin
affect
neg
report
individu
report
variou
commerci
experiment
pasteurella
sp
vaccin
includ
report
signific
efficaci
field
studi
streptomycindepend
live
pasteurella
sp
vaccin
intraderm
administ
live
p
haemolytica
vaccin
loo
altern
field
studi
p
haemolytica
capsular
antigen
vaccin
fail
show
signific
health
effect
studi
use
tissu
culturederiv
p
haemolytica
bacterin
current
avail
pasteurella
sp
vaccin
reliabl
peerreview
report
field
trial
examin
clinic
effect
north
american
beef
cattl
base
research
use
scientif
valid
method
clinic
relev
outcom
report
lack
field
efficaci
earlier
pasteurella
sp
also
report
increas
health
problem
follow
vaccin
earlier
pasteurella
sp
bacterin
howev
studi
mention
whether
treatment
assign
random
experiment
unit
unclear
make
valid
data
analysi
suspect
dose
time
requir
optim
immun
day
follow
booster
dose
valu
compromis
use
feedlot
arriv
program
paradox
avail
data
support
use
p
haemolytica
toxoid
arriv
current
consensu
best
administ
least
prime
dose
sometim
booster
dose
wean
vaccin
antigen
brd
prophylaxi
result
field
trial
evalu
efficaci
h
somnu
bacterin
conflict
one
group
investig
report
neg
effect
singl
vaccin
commerci
h
somnu
bacterin
significantli
anim
group
calv
vaccin
treat
respiratori
diseas
compar
group
unvaccin
control
calv
group
calv
vaccin
twice
interv
find
conflict
earlier
report
author
signific
differ
number
anim
treat
found
group
calv
immun
commerci
h
somnu
bacterin
group
nonimmun
control
calv
convers
investig
report
earlier
morbid
number
anim
treat
respiratori
diseas
significantli
reduc
group
calv
vaccin
commerci
h
somnu
bacterin
arriv
feedlot
revaccin
day
later
compar
morbid
group
vaccin
twice
bival
p
haemolytica
p
multocida
bacterin
unvaccin
control
abil
h
somnu
vaccin
reduc
brd
feedlot
unit
state
may
limit
low
incid
sporad
natur
diseas
although
studi
demonstr
vaccin
efficaci
shown
vaccin
efficaci
use
septicem
challeng
shown
efficaci
experiment
respiratori
challeng
date
howev
efficaci
unequivoc
demonstr
wellcontrol
trial
us
field
set
logic
assum
vaccin
subject
dose
time
limit
pasteurella
sp
vaccin
clear
consensu
usag
field
trial
carri
vaccin
receiv
multipl
antigen
make
imposs
determin
effect
individu
antigen
subdivid
two
broad
group
vaccin
administ
near
time
feedlot
arriv
vaccin
administ
sever
week
feedlot
arriv
assum
valid
design
execut
analysi
interpret
first
group
fairli
straightforward
studi
arriv
vaccin
suggest
affect
may
even
compromis
health
perform
welldesign
studi
use
ibr
mlv
viru
vaccin
along
p
haemolytica
toxoid
fail
show
health
perform
benefit
support
find
multiyear
observ
studi
ontario
canada
report
administr
respiratori
vaccin
ibr
viru
viru
sp
viru
calv
vaccin
within
week
arriv
associ
increas
risk
mortal
rr
contrast
subcutan
vaccin
p
haemolytica
h
somnu
vaccin
arriv
reduc
brd
complex
morbid
second
type
mix
antigen
studi
vaccin
administ
sever
week
feedlot
arriv
often
part
precondit
prewean
studi
unvaccin
similarli
manag
group
rare
includ
studi
effect
manag
intervent
prewean
bunk
acclim
total
confound
vaccin
effect
henc
imposs
know
intervent
account
improv
health
perform
vaccin
inject
ensur
anim
expos
antigen
contain
vaccin
ensur
protect
immun
respons
ensu
two
key
compon
requir
success
immun
efficaci
vaccin
immunocompet
anim
achiev
protect
immun
respons
everi
pathogen
everi
anim
popul
probabl
imposs
sever
reason
even
possibl
would
like
costprohibit
base
pathogenesi
pathogen
requir
individu
popul
immun
vaccin
efficaci
one
exampl
infecti
noncommunic
diseas
tetanu
pathogen
especi
highli
contagi
reduc
number
suscept
anim
critic
threshold
may
suffici
vaccin
efficaci
prevent
diseas
outbreak
concept
herd
immun
vaccin
may
seem
ineffect
contain
antigen
induc
protect
immun
diseasecaus
agent
current
challeng
calf
respiratori
pathogen
influenc
calf
health
vaccin
avail
chlamydia
situat
antigen
differ
strain
speci
pathogen
chang
antigen
organ
display
may
compromis
vaccin
efficaci
one
exampl
genet
antigen
instabl
bvd
viru
instabl
thought
contribut
failur
repeat
annual
dose
inactiv
viru
vaccin
protect
anim
infect
mani
infecti
agent
cattl
immunolog
import
antigen
rel
stabl
like
caus
vaccin
ineffect
improp
storag
handl
must
store
administ
vaccin
accord
manufactur
recommend
risk
reduc
efficaci
done
everyth
properli
care
vaccin
equip
must
care
administ
vaccin
train
session
conduct
ensur
personnel
knowledg
proper
locat
techniqu
vaccin
administr
intramuscular
inject
made
behind
calf
front
leg
subcutan
rout
use
whenev
allow
label
instruct
gener
rule
smallest
needl
product
easili
deliv
use
thin
wateri
product
isgaug
needl
work
well
strict
attent
proper
restraint
chang
needl
keep
sharp
critic
use
isgaug
needl
needl
length
adjust
calf
size
inject
rout
intramuscular
inject
given
losin
needl
except
case
small
calv
iin
needl
use
subcutan
inject
made
needl
shorter
needl
chang
whenev
becom
dull
barb
bent
clean
needl
use
refil
syring
avoid
contamin
vaccin
bottl
good
handl
facil
help
minim
inject
site
reaction
ensur
cattl
adequ
restrain
therebi
prevent
movement
calf
struggl
inject
sanit
import
compon
vaccin
plan
help
minim
inject
site
reaction
abscess
contamin
multidos
contain
result
vaccin
inactiv
inject
site
problem
disinfect
inactiv
mlv
vaccin
must
properli
clean
rins
equip
come
contact
vaccin
time
vaccin
administr
also
influenc
percept
vaccin
effect
anim
incub
diseas
expos
diseasecaus
agent
soon
follow
vaccin
may
get
sick
vaccin
seem
ineffect
take
sever
day
anim
immun
system
respond
vaccin
anim
protect
especi
calf
immunolog
naiv
experiment
give
enough
diseasecaus
organ
caus
diseas
even
immun
anim
cattl
assembl
close
quarter
amount
diseas
agent
expos
may
quit
larg
result
diseas
even
immun
anim
summari
specif
vaccin
recommend
made
veterinarian
familiar
manag
oper
includ
type
cattl
handl
diseas
problem
typic
experienc
cookbook
solut
finetun
program
includ
exclud
certain
vaccin
requir
identif
specif
diseas
entiti
present
oper
requir
good
record
complet
postmortem
examin
good
diagnost
support
system
effect
manag
optim
immunocompet
time
vaccin
administr
import
select
correct
antigen
type
vaccin
use
